THE VALUE OF IMMUNE INHIBITORY RECEPTOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 EXPRESSION IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC DIFFERENTIATION
Deghady, A., elhadidi, A., Ghallab, O., Abd Elaziz, A. (2022). THE VALUE OF IMMUNE INHIBITORY RECEPTOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 EXPRESSION IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC DIFFERENTIATION. EKB Journal Management System, 4(3), 32-33. doi: 10.21608/alexpo.2022.161388.1466
Akram Abdel Moneim Deghady; abeer shawky mohamed elhadidi; Omar Mohamed Ghallab; Asmaa Elsayed Abd Elaziz. "THE VALUE OF IMMUNE INHIBITORY RECEPTOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 EXPRESSION IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC DIFFERENTIATION". EKB Journal Management System, 4, 3, 2022, 32-33. doi: 10.21608/alexpo.2022.161388.1466
Deghady, A., elhadidi, A., Ghallab, O., Abd Elaziz, A. (2022). 'THE VALUE OF IMMUNE INHIBITORY RECEPTOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 EXPRESSION IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC DIFFERENTIATION', EKB Journal Management System, 4(3), pp. 32-33. doi: 10.21608/alexpo.2022.161388.1466
Deghady, A., elhadidi, A., Ghallab, O., Abd Elaziz, A. THE VALUE OF IMMUNE INHIBITORY RECEPTOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 EXPRESSION IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC DIFFERENTIATION. EKB Journal Management System, 2022; 4(3): 32-33. doi: 10.21608/alexpo.2022.161388.1466

THE VALUE OF IMMUNE INHIBITORY RECEPTOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 EXPRESSION IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC DIFFERENTIATION

ALEXMED ePosters
Article 3, Volume 4, Issue 3, September 2022, Page 32-33  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.161388.1466
View on SCiNiTO View on SCiNiTO
Authors
Akram Abdel Moneim Deghady1; abeer shawky mohamed elhadidi2; Omar Mohamed Ghallab3; Asmaa Elsayed Abd Elaziz email 1
1Department of Clinical and Chemical Pathology, University of Alexandria
2department of chemical and clinical pathology, Faculty of medicine.
3Department of Hematology*, Faculty of Medicine, University of Alexandria
Abstract
Acute myeloid leukemia (AML) represents a heterogeneous disease characterized by clonal proliferation of abnormal blast cells in the bone marrow interfering with the production of normal hematopoietic cells. The 2017 World Health Organization (WHO) classification includes four major entities: AML with recurrent genetic abnormalities, AML with myelodysplasia related changes, therapy-related myeloid neoplasms, and AML-not otherwise specified (NOS). A subset of AML-NOS is AML with monocytic differentiation has a high risk of extra medullary infiltration, high leukocytic count and specific cytogenetic abnormalities. Flowcytometric (FC) immunophenotyping is suited for identification of monocytes by available antibodies such as CD11b, CD13, CD4, CD14, CD15, CD34, CD36, CD64, CD11c and CD117. However, neoplastic monocytes variably express these markers. The ILT3 molecule is a transmembrane protein immune inhibitory receptor expressed by APCs as monocytes and DCs. Therefore, the current study was designed to investigate the usefulness of ILT3 expression to distinguish AML with monocytic differentiation from other types of AML.
Keywords
Acute myeloid leukemia (AML); monocytic; ILT3
Supplementary Files
Statistics
Article View: 141